Boniva, Bondronat(ibandronic acid)
Bondronat, Bonviva, Iasibon, Ibandronate, Ibandronic Acid (ibandronic acid) is a small molecule pharmaceutical. Ibandronic acid was first approved as Bondronat on 1996-06-25. It is used to treat postmenopausal osteoporosis in the USA. It has been approved in Europe to treat bone fractures, breast diseases, breast neoplasms, calcium metabolism disorders, and hypercalcemia amongst others.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| ibandronate sodium | ANDA | 2024-01-31 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| postmenopausal osteoporosis | EFO_0003854 | D015663 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
M: Musculo-skeletal system drugs
— M05: Drugs for treatment of bone diseases
— M05B: Drugs affecting bone structure and mineralization
— M05BA: Bisphosphonate drugs affecting bone structure and mineralization
— M05BA06: Ibandronic acid
— M05BB: Bisphosphonates, combinations affecting bone structure and mineralization
— M05BB09: Ibandronic acid and colecalciferol
HCPCS
No data
Clinical
Clinical Trials
85 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postmenopausal osteoporosis | D015663 | EFO_0003854 | — | — | 2 | 6 | 16 | 4 | 28 |
| Osteoporosis | D010024 | HP_0000939 | M81.0 | — | 2 | 4 | 6 | 8 | 19 |
| Bone neoplasms | D001859 | EFO_0003820 | D16 | — | 2 | 4 | 2 | — | 8 |
| Metabolic bone diseases | D001851 | HP_0000938 | — | — | — | 1 | 2 | — | 3 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | — | 1 | 1 | 2 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | — | — | 1 | — | 1 |
| Systemic lupus erythematosus | D008180 | HP_0002725 | M32 | — | — | — | 1 | — | 1 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | — | 1 | — | 1 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 3 | 5 | — | 3 | 11 |
| Pain | D010146 | EFO_0003843 | R52 | — | 1 | 4 | — | — | 5 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 2 | 2 | — | — | 4 |
| Neoplasms | D009369 | — | C80 | — | — | 3 | — | — | 3 |
| Hypercalcemia | D006934 | HP_0003072 | E83.52 | — | — | 2 | — | — | 2 |
| Osteonecrosis | D010020 | EFO_0004259 | M87 | — | — | 1 | — | — | 1 |
| Multiple myeloma | D009101 | — | C90.0 | — | — | 1 | — | — | 1 |
| Hematologic neoplasms | D019337 | — | — | — | — | 1 | — | — | 1 |
| Prostatic neoplasms | D011471 | — | C61 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | — | — | — | 1 | 4 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Femoral fractures | D005264 | — | S72 | — | — | — | — | 1 | 1 |
| Bisphosphonate-associated osteonecrosis of the jaw | D059266 | — | — | — | — | — | — | 1 | 1 |
| Esophageal neoplasms | D004938 | — | C15 | — | — | — | — | 1 | 1 |
| Adenocarcinoma | D000230 | — | — | — | — | — | — | 1 | 1 |
| Squamous cell carcinoma | D002294 | — | — | — | — | — | — | 1 | 1 |
| Squamous cell neoplasms | D018307 | — | — | — | — | — | — | 1 | 1 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 1 | 1 |
| Mortality | D009026 | EFO_0004352 | — | — | — | — | — | 1 | 1 |
| Drug therapy | D004358 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ibandronic acid |
| INN | ibandronic acid |
| Description | Ibandronic acid is a bisphosphonate medication used in the prevention and treatment of osteoporosis and metastasis-associated skeletal fractures in people with cancer. It may also be used to treat hypercalcemia (elevated blood calcium levels). It is typically formulated as its sodium salt ibandronate sodium.
|
| Classification | Small molecule |
| Drug class | androgens |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O |
Identifiers
| PDB | — |
| CAS-ID | 114084-78-5 |
| RxCUI | 115264 |
| ChEMBL ID | CHEMBL997 |
| ChEBI ID | — |
| PubChem CID | 60852 |
| DrugBank | DB00710 |
| UNII ID | UMD7G2653W (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Ibandronic acid
+
Ibandronate
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,025 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
25,517 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use